Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule

Sanford-Burnham Medical Research Institute CEO Perry Nisen

Working on a new initiative to move drugs out of discovery and into the clinic, Sanford-Burnham Medical Research Institute has struck a deal with Daiichi Sankyo to advance a new cardio drug into human studies.

Sanford-Burnham's Conrad Prebys Center for Chemical Genomics was credited with the discovery of the small molecule, which Sanford-Burnham rather cryptically notes may help deal with a consequence of cardiometabolic disease. And the research center, which like others has been struggling to obtain sufficient financing, is hopeful that this initial pact will help trigger more such industry development deals.

"The inhibitor is the product of a deliberate initiative at Sanford-Burnham to enable the process of translating basic research discoveries made by the Institute's researchers into novel therapeutics," said Dr. Perry Nisen, CEO of Sanford-Burnham, in a statement. "This outcome is the first of a number of promising candidates that are emerging from our faculty's fundamental research and progressing through our discovery pipeline. We are all very excited that Daiichi Sankyo is now working with us to accelerate the pace at which this drug candidate will move into the clinic."

Sanford-Burnham initially struck up a collaboration with Daiichi Sankyo last year.

The Japanese pharma company has focused on cardiometabolics as a core field and set out to work with the institute under a 3-year pact that began last May.

- here's the release